JUBLPHARMAPharmaceuticals
Jubilant Pharmova Ltd — PE Ratio & Valuation Analysis
₹816.45
-1.80%
Current P/E35.47xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E87.4x59.4% below avg
⚠️
11.6% Premium to Industry
JUBLPHARMA P/E 35.47x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹52.85 | ₹1073 | 20.3x |
| 2024 | ₹4.86 | ₹1105 | 227.4x |
| 2022 | ₹26.00 | ₹375 | 14.4x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Jubilant Pharmova Ltd Valuation
Jubilant Pharmova Ltd (JUBLPHARMA) currently trades at 35.47x earnings. The Pharmaceuticals sector average PE is 31.77x. JUBLPHARMA commands a premium, reflecting high growth expectations. Historically, JUBLPHARMA has traded at an average PE of 87.4x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
9.55%
Dividend Yield
0.45%
More on Jubilant Pharmova Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.